In the last trading session, 1.26 million shares of the Lexeo Therapeutics Inc (NASDAQ:LXEO) were traded, and its beta was 1.38. Most recently the company’s share price was $4.64, and it changed around -$0.07 or -1.49% from the last close, which brings the market valuation of the company to $154.05M. LXEO currently trades at a discount to its 52-week high of $19.50, offering almost -320.26% off that amount. The share price’s 52-week low was $1.45, which indicates that the current value has risen by an impressive 68.75% since then. We note from Lexeo Therapeutics Inc’s average daily trading volume that its 10-day average is 0.82 million shares, with the 3-month average coming to 807.53K.
Lexeo Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.17. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended LXEO as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Lexeo Therapeutics Inc is expected to report earnings per share of -0.77 for the current quarter.
Lexeo Therapeutics Inc (NASDAQ:LXEO) trade information
Instantly LXEO has showed a red trend with a performance of -1.49% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 5.55 on recent trading dayincreased the stock’s daily price by 16.4%. The company’s shares are currently down -29.48% year-to-date, but still up 26.09% over the last five days. On the other hand, Lexeo Therapeutics Inc (NASDAQ:LXEO) is 57.56% up in the 30-day period. We can see from the shorts that 2.94 million shares have been sold at a short interest cover period of 2.25 day(s).
The consensus price target as assigned by Wall Street analysts is $28, which translates to bulls needing to increase their stock price by 83.43% from its current value. Analyst projections state that LXEO is forecast to be at a low of $28 and a high of $28.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -99.98%. Lexeo Therapeutics Inc earnings are expected to increase by 0.59% in 2025, but the outlook is positive 0.60% per year for the next five years.
LXEO Dividends
Lexeo Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-23.
Lexeo Therapeutics Inc (NASDAQ:LXEO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.26% of Lexeo Therapeutics Inc shares, and 111.52% of them are in the hands of institutional investors. The stock currently has a share float of 112.94%. Lexeo Therapeutics Inc stock is held by 116.0 institutions, with EVENTIDE ASSET MANAGEMENT, LLC being the largest institutional investor. By 2024-06-30, it held 10.2089% of the shares, which is about 3.37 million shares worth $54.04 million.
JANUS HENDERSON GROUP PLC, with 9.5873% or 3.16 million shares worth $50.73 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.23 shares worth $5.73 million, making up 3.72% of all outstanding shares. On the other hand, JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund held roughly 682.04 shares worth around $3.16 million, which represents about 2.05% of the total shares outstanding.
